10-Q/A: Bioxytran Files Amended Quarterly Report to Correct Subsequent Events Disclosure

Bioxytran, Inc. files an amendment to its Q1 2024 quarterly report to correct a date error in the subsequent events disclosure related to common stock issuances.

Summary

• Bioxytran, Inc. has filed an amendment (Form 10-Q/A) to its quarterly report for the period ended March 31, 2024.
• The amendment corrects Note 12 regarding subsequent events, specifically the month of issuance for shares of common stock.
• The original filing incorrectly stated the month as May, which has been corrected to April.
• The amendment includes new certifications from the CEO and CFO as required by Section 302 of the Sarbanes-Oxley Act.
• The company's management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.
• On April 15, 2024, the Company issued 173,077 shares of Common Stock for a cash investment of $18,000, or $0.104/share.
• On April 15, 2024, the Company issued 479,192 shares of Common Stock in conversion of a note of $61,500 and $795 in interest, or $0.13/share.
• On April 4, 2024, the Company issued 1,000,000 shares of Common Stock to a consultant as payment for a 12-month investor relations agreement.
• On April 5, 2024 the Company corrected an issuance of 50,000 made on March 27, 2023.
• On April 19, 2024, the Company issued 241,938 shares of Common Stock to affiliates for their service in the Board of Directors during the first quarter of 2024.
• On April 19, 2024, the Company issued 86,246 shares of Common Stock to non-affiliates for their services during the first quarter of 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is primarily a correction of a clerical error. The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Positives

• The company is correcting errors in its filings, demonstrating a commitment to accurate financial reporting.
• The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Risks

• The need to amend the quarterly report suggests potential weaknesses in internal controls over financial reporting.
• The company is issuing a significant number of shares for relatively small amounts of cash, which could dilute existing shareholders.

Future Outlook

Management sees no further subsequent events requiring disclosure.

Industry Context

This filing is a routine amendment to correct a specific error in financial reporting. It doesn't necessarily reflect broader industry trends but highlights the importance of accurate and timely disclosures, especially for smaller reporting companies like Bioxytran.

Related Party Transactions

• On April 19, 2024, the Company issued 241,938 shares of Common Stock to affiliates for their service in the Board of Directors during the first quarter of 2024.
• On April 19, 2024, the Company issued 86,246 shares of Common Stock to non-affiliates for their services during the first quarter of 2024.

Stakeholder Impact

• Shareholders should be aware of the correction to the financial statements.
• The issuance of new shares will dilute existing shareholders.

Key Dates

Keywords

Form 10-Q/A, amendment, quarterly report, Bioxytran, common stock, subsequent events, share issuance, financial statements